208 related articles for article (PubMed ID: 8161776)
1. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.
Gruss HJ; Boiani N; Williams DE; Armitage RJ; Smith CA; Goodwin RG
Blood; 1994 Apr; 83(8):2045-56. PubMed ID: 8161776
[TBL] [Abstract][Full Text] [Related]
2. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
3. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
4. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.
Gattei V; Degan M; Gloghini A; De Iuliis A; Improta S; Rossi FM; Aldinucci D; Perin V; Serraino D; Babare R; Zagonel V; Gruss HJ; Carbone A; Pinto A
Blood; 1997 Mar; 89(6):2048-59. PubMed ID: 9058727
[TBL] [Abstract][Full Text] [Related]
5. Sequential development of Hodgkin's disease and CD30+ diffuse large B-cell lymphoma in a patient with MALT-type lymphoma: evidence of different clonal origin of single microdissected Reed-Sternberg cells.
Parrens M; Vergier B; Fitoussi O; Lahet C; Belleannee G; Marit G; Dubus P; de Mascarel A; Delfau-Larue MH; Merlio JP
Am J Surg Pathol; 2002 Dec; 26(12):1634-42. PubMed ID: 12459631
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study.
Carbone A; Dolcetti R; Gloghini A; Maestro R; Vaccher E; di Luca D; Tirelli U; Boiocchi M
Hum Pathol; 1996 Feb; 27(2):133-46. PubMed ID: 8617454
[TBL] [Abstract][Full Text] [Related]
7. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.
Wendtner CM; Schmitt B; Gruss HJ; Druker BJ; Emmerich B; Goodwin RG; Hallek M
Cancer Res; 1995 Sep; 55(18):4157-61. PubMed ID: 7545087
[TBL] [Abstract][Full Text] [Related]
8. Expression of Epstein-Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency.
Kanavaros P; Jiwa M; van der Valk P; Walboomers J; Horstman A; Meijer CJ
Hum Pathol; 1993 Jul; 24(7):725-9. PubMed ID: 8100553
[TBL] [Abstract][Full Text] [Related]
9. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma.
Hsu PL; Hsu SM
Lab Invest; 2000 Jul; 80(7):1111-9. PubMed ID: 10908157
[TBL] [Abstract][Full Text] [Related]
10. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines.
Delabie J; Ceuppens JL; Vandenberghe P; de Boer M; Coorevits L; De Wolf-Peeters C
Blood; 1993 Nov; 82(9):2845-52. PubMed ID: 7693051
[TBL] [Abstract][Full Text] [Related]
11. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.
van den Berg A; Visser L; Poppema S
Am J Pathol; 1999 Jun; 154(6):1685-91. PubMed ID: 10362793
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease.
Gruss HJ; Hirschstein D; Wright B; Ulrich D; Caligiuri MA; Barcos M; Strockbine L; Armitage RJ; Dower SK
Blood; 1994 Oct; 84(7):2305-14. PubMed ID: 7522624
[TBL] [Abstract][Full Text] [Related]
13. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel.
Chittal SM; Caverivière P; Schwarting R; Gerdes J; Al Saati T; Rigal-Huguet F; Stein H; Delsol G
Am J Surg Pathol; 1988 Jan; 12(1):9-21. PubMed ID: 2827535
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family.
Schneider C; Hübinger G
Leuk Lymphoma; 2002 Jul; 43(7):1355-66. PubMed ID: 12389614
[TBL] [Abstract][Full Text] [Related]
17. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
18. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
Wood GS; Hardman DL; Boni R; Dummer R; Kim YH; Smoller BR; Takeshita M; Kikuchi M; Burg G
Blood; 1996 Sep; 88(5):1765-70. PubMed ID: 8781433
[TBL] [Abstract][Full Text] [Related]
19. Detection of Epstein-Barr virus genome in Ki-1 (CD30)-positive, large-cell anaplastic lymphomas using the polymerase chain reaction.
Ross CW; Schlegelmilch JA; Grogan TM; Weiss LM; Schnitzer B; Hanson CA
Am J Pathol; 1992 Aug; 141(2):457-65. PubMed ID: 1323222
[TBL] [Abstract][Full Text] [Related]
20. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro.
Matsumoto K; Terakawa M; Miura K; Fukuda S; Nakajima T; Saito H
J Immunol; 2004 Feb; 172(4):2186-93. PubMed ID: 14764685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
